Robert Blum Sells 7,500 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $76.76, for a total value of $575,700.00. Following the transaction, the chief executive officer owned 377,820 shares in the company, valued at approximately $29,001,463.20. This trade represents a 1.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Trading Down 1.3%

Shares of Cytokinetics stock opened at $76.45 on Wednesday. The firm has a fifty day simple moving average of $79.10 and a 200-day simple moving average of $71.15. Cytokinetics, Incorporated has a 1-year low of $33.17 and a 1-year high of $88.31. The stock has a market capitalization of $9.51 billion, a price-to-earnings ratio of -10.59 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same quarter in the previous year, the business posted ($1.12) earnings per share. The business’s quarterly revenue was down 57.1% compared to the same quarter last year. As a group, research analysts predict that Cytokinetics, Incorporated will post -6 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CYTK shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Friday, July 17th. Stifel Nicolaus boosted their price objective on Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. HC Wainwright increased their target price on Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Needham & Company LLC increased their target price on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.15.

Institutional Trading of Cytokinetics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Cytokinetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock worth $765,538,000 after purchasing an additional 191,336 shares during the period. Royce & Associates LP increased its holdings in Cytokinetics by 44.3% in the 4th quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company’s stock valued at $9,177,000 after buying an additional 44,343 shares during the period. Norges Bank bought a new stake in Cytokinetics in the 4th quarter valued at $51,281,000. GW&K Investment Management LLC raised its stake in shares of Cytokinetics by 161.5% in the 4th quarter. GW&K Investment Management LLC now owns 472,363 shares of the biopharmaceutical company’s stock valued at $30,015,000 after buying an additional 291,693 shares in the last quarter. Finally, Eventide Asset Management LLC raised its stake in shares of Cytokinetics by 181.9% in the 4th quarter. Eventide Asset Management LLC now owns 479,611 shares of the biopharmaceutical company’s stock valued at $30,473,000 after buying an additional 309,503 shares in the last quarter.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The analyst improved its Q3 2026 EPS estimate to $(1.65) from $(1.80), Q4 to $(1.55) from $(1.86), and full-year 2026 to $(6.38) from $(6.86). HC Wainwright also retained a $140 price target, well above recent trading levels, signaling confidence in Cytokinetics’ development pipeline and future prospects.
• Positive Sentiment: Other analysts have recently increased their price targets. Citizens JMP raised its target to $110, Truist Financial lifted its target to $112, and UBS upgraded the stock to Buy with a $115 target. The analyst consensus remains “Moderate Buy,” with an average target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
• Neutral Sentiment: Reported short-interest data showed no measurable short position. The filing listed short interest at zero shares and a zero-day short-interest ratio, but the reported percentage change was unavailable. Consequently, the data provides little actionable information about potential short-covering or bearish positioning.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares worth approximately $575,700. The transaction reduced his direct holdings by 1.95%, which can create a modest negative signal for investors. However, the sale was executed under a pre-arranged Rule 10b5-1 trading plan, making it less indicative of a discretionary bearish view. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.